Advertisement
Survey Series
For Advertisers
|
|
||||
|
European Biotechs Face a Cash Crunch
Lack of late-stage funding hinders their ability to succeed
Email: Clare Kittredge - ckittredge@the-scientist.com The Scientist 2005, 19(13):44
|
||||
|
|
||||
|
European biotech companies are more likely than their American counterparts to fail at the 3- to 5-year stage, according to a UK-based think tank. Part of the problem is that the European Union's financing institution is putting money into biotech startups without making sure they can attract international backing when the seed money runs out.
|
|
|||||||||
|
|||||||||
|
